Table 1.

Patient demographics and disease characteristics

	mM		mRCC		Total
	n = 170	%	n = 192	%	n = 362	%
Gender
Male	70	41	144	75	214	59
Female	100	59	48	25	148	41
Age
<65	149	88	168	88	317	88
≥65	21	12	24	13	45	12
Median	54	NA	56	NA	55	NA
Range	20–79	NA	19–74	NA	19–79	NA
Race
White	165	97	181	94	346	96
Black	4	2	2	1	6	2
Other	1	1	7	4	8	2
Decline	0	0	2	1	2	1
ECOG PS a
0	124	73	156	82	280	78
1	44	26	34	18	78	22
2	2	1	1	1	3	1
Missinga	0	0	1	1	1	0
Stage b
IIIc	8	5	NA	NA	8	3
III/III NOS	0	0	2	2	2	1
IIIb/IVa	6	4	4	4	10	4
IV/IVNOS	36	21	89	94	125	47
M1a	11	6	NA	NA	11	4
M1b	28	16	NA	NA	28	11
M1c	79	46	NA	NA	79	30
Other, specify	2	1	NA	NA	2	1
Missingb	0	0	97	NA	97	37

	mM		mRCC		Total
Had mutation testing
No	112	66	NA	NA	112	31
Yesc	58	34	NA	NA	58	16
BRAF+
Noc	17	30	NA	NA	17	30
Not testedc	1	2	NA	NA	1	2
Yesc	40	70	NA	NA	40	70
Site of metastasis
Skin, lungs, LNs only	48	28	73	38	121	33
Other including skin, lungs, LNs	119	70	79	41	198	55
Not reported	3	2	40	21	43	12
Prior therapy d
Surgery	118	69	183	95	301	83
Radiation	49	29	15	8	64	18
Chemotherapy	32	19	5	3	37	10
Other immunotherapy	58	34	5	3	63	17
Targeted therapy	3	2	25	13	28	8
Blinded RCT	3	2	3	2	6	2
Other	3	2	1	1	4	1
Untreated	34	20	5	3	39	11

^aECOG PS based on patients with available data

^bSites were not required to enter in tumor stage for mRCC patients. Calculations were from patients with available data (95). Ninety-seven patients did not have tumor stage data

^cBRAF mutation percentage was calculated from patients who had mutation testing

^dPatients may have had multiple prior therapies. Percentages were calculated based on number of patients

NA not available, ECOG PS Eastern Cooperative Oncology Group performance status, NOS not otherwise specified, LNs lymph nodes, RCT research clinical trial